181 related articles for article (PubMed ID: 30915533)
1. Differences in intra-tumoral macrophage infiltration and radiotherapy response among intrinsic subtypes in pT1-T2 breast cancers treated with breast-conserving surgery.
Garvin S; Vikhe Patil E; Arnesson LG; Oda H; Hedayati E; Lindström A; Shabo I
Virchows Arch; 2019 Aug; 475(2):151-162. PubMed ID: 30915533
[TBL] [Abstract][Full Text] [Related]
2. Tumor cell expression of CD163 is associated to postoperative radiotherapy and poor prognosis in patients with breast cancer treated with breast-conserving surgery.
Garvin S; Oda H; Arnesson LG; Lindström A; Shabo I
J Cancer Res Clin Oncol; 2018 Jul; 144(7):1253-1263. PubMed ID: 29725763
[TBL] [Abstract][Full Text] [Related]
3. GATA-3 expression in breast cancer is related to intratumoral M2 macrophage infiltration and tumor differentiation.
Oda H; Hedayati E; Lindström A; Shabo I
PLoS One; 2023; 18(3):e0283003. PubMed ID: 36996051
[TBL] [Abstract][Full Text] [Related]
4. M2-macrophage infiltration and macrophage traits of tumor cells in urinary bladder cancer.
Aljabery F; Olsson H; Gimm O; Jahnson S; Shabo I
Urol Oncol; 2018 Apr; 36(4):159.e19-159.e26. PubMed ID: 29288002
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study.
Sanpaolo P; Barbieri V; Genovesi D
Eur J Surg Oncol; 2011 Oct; 37(10):876-82. PubMed ID: 21824742
[TBL] [Abstract][Full Text] [Related]
6. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
[TBL] [Abstract][Full Text] [Related]
7. Tumor-associated macrophages are strongly related to vascular invasion, non-luminal subtypes, and interval breast cancer.
Klingen TA; Chen Y; Aas H; Wik E; Akslen LA
Hum Pathol; 2017 Nov; 69():72-80. PubMed ID: 28923419
[TBL] [Abstract][Full Text] [Related]
8. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy.
Bane AL; Whelan TJ; Pond GR; Parpia S; Gohla G; Fyles AW; Pignol JP; Pritchard KI; Chambers S; Levine MN
Ann Oncol; 2014 May; 25(5):992-8. PubMed ID: 24562444
[TBL] [Abstract][Full Text] [Related]
9. [Evidence-based radiotherapy in the treatment of early-stage invasive breast cancer: traditional clinical features and biomarkers].
Fodor J
Magy Onkol; 2009 Mar; 53(1):7-14. PubMed ID: 19318321
[TBL] [Abstract][Full Text] [Related]
10. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
[TBL] [Abstract][Full Text] [Related]
11. Impact of age, intrinsic subtype and local treatment on long-term local-regional recurrence and breast cancer mortality among low-risk breast cancer patients.
Laurberg T; Alsner J; Tramm T; Jensen V; Lyngholm CD; Christiansen PM; Overgaard J
Acta Oncol; 2017 Jan; 56(1):59-67. PubMed ID: 27846764
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
Nguyen PL; Taghian AG; Katz MS; Niemierko A; Abi Raad RF; Boon WL; Bellon JR; Wong JS; Smith BL; Harris JR
J Clin Oncol; 2008 May; 26(14):2373-8. PubMed ID: 18413639
[TBL] [Abstract][Full Text] [Related]
13. [Clinical characteristics and prognosis of patients with ipsilateral breast tumor recurrence after breast conservation therapy].
Sun GY; Wang SL; Tang Y; Jin J; Song YW; Liu YP; Wang WH; Fang H; Chen SY; Ren H; Liu XF; Yu ZH; Li YX
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):352-358. PubMed ID: 29860762
[No Abstract] [Full Text] [Related]
14. Predictive value of estrogen receptor status as assessed by ligand-binding assay in patients with early-stage breast cancer treated with breast conserving surgery and radiation therapy.
Takei H; Horiguchi J; Maemura M; Koibuchi Y; Oyama T; Yokoe T; Iino Y; Morishita Y
Oncol Rep; 2002; 9(2):375-8. PubMed ID: 11836611
[TBL] [Abstract][Full Text] [Related]
15. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
Zhang HM; Zhang BN; Xuan LX; Zhao P
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
[TBL] [Abstract][Full Text] [Related]
16. Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers.
Watanabe T; Hida AI; Inoue N; Imamura M; Fujimoto Y; Akazawa K; Hirota S; Miyoshi Y
Breast Cancer Res Treat; 2018 Feb; 168(1):135-145. PubMed ID: 29168063
[TBL] [Abstract][Full Text] [Related]
17. Outcomes Following a Moderately Hypofractionated Adjuvant Radiation (START B Type) Schedule for Breast Cancer in an Unscreened Non-Caucasian Population.
Chatterjee S; Arunsingh M; Agrawal S; Dabkara D; Mahata A; Arun I; Shrimali RK; Achari R; Mallick I; Ahmed R
Clin Oncol (R Coll Radiol); 2016 Oct; 28(10):e165-72. PubMed ID: 27369459
[TBL] [Abstract][Full Text] [Related]
18. The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy.
Alabdulkareem H; Pinchinat T; Khan S; Landers A; Christos P; Simmons R; Moo TA
Breast J; 2018 Mar; 24(2):148-153. PubMed ID: 28707744
[TBL] [Abstract][Full Text] [Related]
19. [Survival of patients with metastatic breast cancer according to pathological types of tumors].
Sánchez R C; Acevedo C F; Petric G M; Galindo A H; Domínguez C F; León R A; Razmilic V D; Ceballos C; Espinoza F; Navarro O ME; Oddó B D; Camus A M
Rev Med Chil; 2014 Apr; 142(4):428-35. PubMed ID: 25117032
[TBL] [Abstract][Full Text] [Related]
20. Expression of matrix metalloproteinases and their inhibitors in different immunohistochemical-based molecular subtypes of breast cancer.
Kim GE; Lee JS; Choi YD; Lee KH; Lee JH; Nam JH; Choi C; Kim SS; Park MH; Yoon JH; Kweon SS
BMC Cancer; 2014 Dec; 14():959. PubMed ID: 25510449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
